BACKGROUND Anticipating and controlling drug-drug interactions (DDIs) in older patients with painful diabetic peripheral neuropaty (pDPN) presents a significant challenge to providers. The purpose of this study was to examine the impact of newly initiated pregabalin or duloxetine treatment on Medicare Advantage Prescription Drug (MAPD) plan pDPN patients' encounters with potential drug-drug int...

The drugs that are currently available to treat neuropathic pain exhibit inadequate efficacy and numerous adverse effects. The present study compared the efficacy of combination therapy with pregabalin and morphine with that of each as a single agent in patients with neuropathic pain. The primary measurement was mean daily pain intensity. Secondary measurements included a pain questionnaire, ad...

BACKGROUND Patients with neuropathic pain (NeP) often receive combination therapy with multiple agents in the hopes of improving both pain and any comorbidities that may be present. While pregabalin is often recommended as a first-line treatment of NeP, few studies have examined the effects of concomitant medications on the efficacy of pregabalin. OBJECTIVE To examine the effects of concomita...

BACKGROUND Pregabalin is an anticonvulsant and analgesic agent that interacts selectively with the voltage-sensitive-Ca(2+)-channel alpha-2-delta subunit. The aim of this study was to evaluate whether the analgesic action of intrathecal (IT) pregabalin is associated with K(ATP) channels in the rat formalin test. METHODS IT PE-10 catheters were implanted in male Sprague-Dawley rats (250-300 g)...

INTRODUCTION Pregabalin efficacy and safety as an adjunctive treatment for partial seizures was evaluated using an open-label, flexible-dose. STUDY DESIGN In 98 adults with refractory partial epilepsy taking 1-3 anti-epileptic drugs with ≥2 seizures during an 8-week baseline period. METHODS Pregabalin was increased to ≤600 mg/day during a 9-week dose optimization period with dosage maintain...

Pregabalin and gabapentin share a similar mechanism of action, inhibiting calcium influx and subsequent release of excitatory neurotransmitters; however, the compounds differ in their pharmacokinetic and pharmacodynamic characteristics. Gabapentin is absorbed slowly after oral administration, with maximum plasma concentrations attained within 3-4 hours. Orally administered gabapentin exhibits s...

Pregabalin, (S)-3-(aminomethyl)-5-methylhexanoic acid, binds with high affinity to the α(2)δ subunit of voltage-gated calcium channels and exerts analgesic, anxiolytic, and antiseizure activities. Two-year carcinogenicity studies were completed in B6C3F1 and CD-1 mice and two separate studies in Wistar rats. Doses in mice were 200, 1000, and 5000 mg/kg/day, with systemic exposures (AUC(0-24 h))...

The present study was planned to investigate the action of pregabalin on voltage-dependent Ca channels (VDCCs) and novel targets (fusion pore formed between the secretory vesicle and the plasma membrane, exocytotic machinery, and mitochondria) that would further explain its inhibitory action on neurotransmitter release. Electrophysiological recordings in the perforated-patch configuration of th...

Pregabalin (PGB), is an antiepileptic and analgesic drug, which is structural analogue of γ-amino-butyric acid. This drug has been approved by Food and Drug Administration for the treatment of central nervous system disorders including epilepsy, fibromyalgia and also for the treatment of neuropathic pain. It was designed as a potent successor to gabapentin. PGB is minimally metabolized and prim...

Neuropathic pain is a chronic condition resulting from neuronal damage. Pregabalin, the (S)-isomer of 3-isobutyl-γ-aminobutyric acid (GABA), is widely used to treat neuropathic pain, despite the occurrence of central nervous system (CNS)-related side effects such as dizziness and somnolence. Here we describe the pharmacology of novel GABA derivatives containing silicon-carbon bonds, silagaba co...